Teresa Morán

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist et al. · Clinical Cancer Research · 2016 · 1.2K citations · Full text

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Matthew J. Niederst, Lecia V. Sequist, John T. Poirier et al. · Nature Communications · 2015 · 619 citations · Full text

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun et al. · Science Translational Medicine · 2013 · 548 citations · Full text